Compare Microchip Technology Inc. (MCHP) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Microchip Technology Inc. vs 10X Genomics Inc — how do they compare? Microchip Technology Inc. trades at $75.55 (market cap $41.01B), while 10X Genomics Inc trades at $80.65 (market cap $10.07B). The key difference: Microchip Technology Inc. is far larger — about 4.1× 10X Genomics Inc's market cap, and Microchip Technology Inc. pays a 2.41% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Microchip Technology Inc. for 63 Days and 10X Genomics Inc for 91 Days on average.
| MCHP | TXG | |
|---|---|---|
Market Cap | $41.01B | $10.07B |
Volume | 9,972,516 | 5,657,286 |
Sector | Technology | Health |
52-Week High | $102.97 | $97.74 |
52-Week Low | $49.02 | $11.48 |
Typical Hold Time | 63 Days | 91 Days |
Enterprise Value | $46.13B | $9.59B |
Dividend Yield | 2.41% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCHP trades at $75.52, down 3.2% over 24 hours, with a bearish technical signal from moving averages. The company reported a net loss of -$500K in 2025, though it has beaten EPS estimates in recent quarters. Analyst consensus is strongly bullish with a $110.50 price target, supported by positive news on product expansions in Ethernet and 48V power portfolios and the completion of the Hailo acquisition.
The outlook is mixed: strong analyst support and strategic expansions in high-growth areas like AI and automotive present upside, but high valuation ratios, significant debt, and recent profitability challenges pose risks. Investor sentiment is cautiously optimistic amid sector tailwinds.
10x Genomics (TXG) trades at $77.28, up 1.55% on the day, with a bearish technical signal from moving averages. The company shows improving fundamentals with revenue of $642.82M in 2025 and a reduced net loss of -$43.54M, while recent news highlights strong demand for its Atera spatial biology platform and a patent victory. Positive earnings beats in recent quarters contrast with a high EV/EBITDA of 249.22, indicating significant growth expectations are priced in.
The outlook is mixed; analyst consensus is neutral with a $74.30 price target slightly below the current price, yet operational cash flow turned strongly positive in 2025. Key risks include persistent net losses, high valuation multiples, and execution on new product launches. The stock's near-term direction hinges on Atera's commercial success and achieving profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
